High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses

Jorge E. Cortes, Hagop M. Kantarjian, Stuart L. Goldberg, Bayard L. Powell, Francis J. Giles, Meir Wetzler, Luke Akard, John M. Burke, Robert Kerr, Mansoor Saleh, August Salvado, Karen McDougall, Maher Albitar, Jerald Radich

Research output: Contribution to journalArticle

Abstract

Purpose: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). Patients and Methods: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70% Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72%) completed the study, 10 patients (9%) discontinued the study because of adverse events, and six patients (5%) discontinued because of unsatisfactory therapeutic effect. Results: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48% of patients achieving MMR by 6 months, 54% by 12 months, and 63% by 18 months. Corresponding complete molecular response rates were 39%, 44%, and 55%, respectively. Median dose-intensity was 98%. Overall, 79% of patients who received at least 90% dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. Conclusion: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.

Original languageEnglish (US)
Pages (from-to)4754-4759
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Issue number28
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Imatinib Mesylate
Therapeutic Uses
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Exanthema
Tumor Burden
Multicenter Studies
Fatigue
Therapeutics
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : High rates of rapid cytogenetic and molecular responses. / Cortes, Jorge E.; Kantarjian, Hagop M.; Goldberg, Stuart L.; Powell, Bayard L.; Giles, Francis J.; Wetzler, Meir; Akard, Luke; Burke, John M.; Kerr, Robert; Saleh, Mansoor; Salvado, August; McDougall, Karen; Albitar, Maher; Radich, Jerald.

In: Journal of Clinical Oncology, Vol. 27, No. 28, 01.10.2009, p. 4754-4759.

Research output: Contribution to journalArticle

Cortes, JE, Kantarjian, HM, Goldberg, SL, Powell, BL, Giles, FJ, Wetzler, M, Akard, L, Burke, JM, Kerr, R, Saleh, M, Salvado, A, McDougall, K, Albitar, M & Radich, J 2009, 'High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses', Journal of Clinical Oncology, vol. 27, no. 28, pp. 4754-4759. https://doi.org/10.1200/JCO.2008.20.3869
Cortes, Jorge E. ; Kantarjian, Hagop M. ; Goldberg, Stuart L. ; Powell, Bayard L. ; Giles, Francis J. ; Wetzler, Meir ; Akard, Luke ; Burke, John M. ; Kerr, Robert ; Saleh, Mansoor ; Salvado, August ; McDougall, Karen ; Albitar, Maher ; Radich, Jerald. / High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : High rates of rapid cytogenetic and molecular responses. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 28. pp. 4754-4759.
@article{af8de084b6424f4f9435d4587ce76c8b,
title = "High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses",
abstract = "Purpose: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). Patients and Methods: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70{\%} Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72{\%}) completed the study, 10 patients (9{\%}) discontinued the study because of adverse events, and six patients (5{\%}) discontinued because of unsatisfactory therapeutic effect. Results: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48{\%} of patients achieving MMR by 6 months, 54{\%} by 12 months, and 63{\%} by 18 months. Corresponding complete molecular response rates were 39{\%}, 44{\%}, and 55{\%}, respectively. Median dose-intensity was 98{\%}. Overall, 79{\%} of patients who received at least 90{\%} dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. Conclusion: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.",
author = "Cortes, {Jorge E.} and Kantarjian, {Hagop M.} and Goldberg, {Stuart L.} and Powell, {Bayard L.} and Giles, {Francis J.} and Meir Wetzler and Luke Akard and Burke, {John M.} and Robert Kerr and Mansoor Saleh and August Salvado and Karen McDougall and Maher Albitar and Jerald Radich",
year = "2009",
month = "10",
day = "1",
doi = "10.1200/JCO.2008.20.3869",
language = "English (US)",
volume = "27",
pages = "4754--4759",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

T2 - High rates of rapid cytogenetic and molecular responses

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop M.

AU - Goldberg, Stuart L.

AU - Powell, Bayard L.

AU - Giles, Francis J.

AU - Wetzler, Meir

AU - Akard, Luke

AU - Burke, John M.

AU - Kerr, Robert

AU - Saleh, Mansoor

AU - Salvado, August

AU - McDougall, Karen

AU - Albitar, Maher

AU - Radich, Jerald

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Purpose: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). Patients and Methods: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70% Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72%) completed the study, 10 patients (9%) discontinued the study because of adverse events, and six patients (5%) discontinued because of unsatisfactory therapeutic effect. Results: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48% of patients achieving MMR by 6 months, 54% by 12 months, and 63% by 18 months. Corresponding complete molecular response rates were 39%, 44%, and 55%, respectively. Median dose-intensity was 98%. Overall, 79% of patients who received at least 90% dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. Conclusion: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.

AB - Purpose: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). Patients and Methods: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70% Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72%) completed the study, 10 patients (9%) discontinued the study because of adverse events, and six patients (5%) discontinued because of unsatisfactory therapeutic effect. Results: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48% of patients achieving MMR by 6 months, 54% by 12 months, and 63% by 18 months. Corresponding complete molecular response rates were 39%, 44%, and 55%, respectively. Median dose-intensity was 98%. Overall, 79% of patients who received at least 90% dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. Conclusion: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.

UR - http://www.scopus.com/inward/record.url?scp=70350442594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350442594&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.20.3869

DO - 10.1200/JCO.2008.20.3869

M3 - Article

C2 - 19720924

AN - SCOPUS:70350442594

VL - 27

SP - 4754

EP - 4759

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -